(FILE 'HOME' ENTERED AT 11:13:12 ON 31 MAY 2001)

FILE 'REGISTRY' ENTERED AT 11:13:23 ON 31 MAY 2001
E ZSEBO KRISZTINA

FILE 'CAPLUS, MEDLINE, BIOSIS, USPATFULL' ENTERED AT 11:16:50 ON 31 MAY 2001
E ZSEBO/AU

L1	56	S	E4
L2	180	S	E5
L3	14	S	(L1 OR L2) AND EMBRYONIC
L4	1	S	E12
L5	1	S	E11
L6	3	S	E10
L7	1	S	E9
L8	1	S	E8
L9	1	S	E7
L10	1	S	E6
L11	23	S	(L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10)
L12	15	S	(L11 OR L2 OR L3) AND EMBRYONIC
L13	12	S	L12 AND ((GROWTH FACTOR) OR GH)
L14	39	S	(METANEPHRIC TISSUE)
L15	0	S	L13 AND L14
L16	2	S	L13 AND TISSUE
L17	8234	S	(EMBRYONIC KIDNEY)
L18	0	S	L13 AND L17
L19	12	S	L13 AND (EMBRYONIC OR KIDNEY)

=> d l19 1-12

L19 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2001 ACS
AN 1991:551874 CAPLUS
DN 115:151874
TI Effects of the steel gene product on mouse primordial germ cells in culture
AU Godin, I.; Deed, R.; Cooke, J.; **Zsebo, K.**; Dexter, M.; Wylie, C. C.
CS Wellcome/CRC Inst., Univ. Cambridge, Cambridge, CB2 1QR, UK
SO Nature (London) (1991), 352(6338), 807-9
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English

L19 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2001 ACS
AN 1991:18592 CAPLUS
DN 114:18592
TI **Embryonic** expression of a hematopoietic **growth factor** encoded by the Sl locus and and the ligand for c-kit
AU Matsui, Yasuhisa; **Zsebo, Kristina M.**; Hogan, Brigid L. M.
CS Med. Sch., Vanderbilt Univ., Nashville, TN, 37232-2172, USA
SO Nature (London) (1990), 347(6294), 667-9
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English

L19 ANSWER 3 OF 12 MEDLINE
AN 92386603 MEDLINE
DN 92386603 PubMed ID: 1381289
TI Derivation of pluripotential **embryonic** stem cells from murine primordial germ cells in culture.
AU Matsui Y; **Zsebo K**; Hogan B L
CS Department of Cell Biology Vanderbilt University Medical School Nashville,
Tennessee 37232.
SO CELL, (1992 Sep 4) 70 (5) 841-7.
Journal code: CQ4; 0413066. ISSN: 0092-8674.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199210
ED Entered STN: 19921023
Last Updated on STN: 19960129
Entered Medline: 19921007

L19 ANSWER 4 OF 12 MEDLINE
AN 92097531 MEDLINE
DN 92097531 PubMed ID: 1721869
TI Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis.
AU Blume-Jensen P; Claesson-Welsh L; Siegbahn A; **Zsebo K M**; Westermark B; Heldin C H
CS Ludwig Institute for Cancer Research, Uppsala, Sweden.
SO EMBO JOURNAL, (1991 Dec) 10 (13) 4121-8.
Journal code: EMB; 8208664. ISSN: 0261-4189.
CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199201
ED Entered STN: 19920223
Last Updated on STN: 20000303
Entered Medline: 19920131

L19 ANSWER 5 OF 12 MEDLINE
AN 91351286 MEDLINE
DN 91351286 PubMed ID: 1715517
TI Effects of the steel gene product on mouse primordial germ cells in culture.
AU Godin I; Deed R; Cooke J; **Zsebo K**; Dexter M; Wylie C C
CS Wellcome/CRC Institute, University of Cambridge, UK.
SO NATURE, (1991 Aug 29) 352 (6338) 807-9.
Journal code: NSC; 0410462. ISSN: 0028-0836.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199110
ED Entered STN: 19911020
Last Updated on STN: 20000303
Entered Medline: 19911001

L19 ANSWER 6 OF 12 MEDLINE
AN 91188350 MEDLINE
DN 91188350 PubMed ID: 1707188
TI Stem cell factor (SCF), a novel hematopoietic **growth factor** and ligand for c-kit tyrosine kinase receptor, maps on human chromosome 12 between 12q14.3 and 12qter.
AU Geissler E N; Liao M; Brook J D; Martin F H; **Zsebo K M**; Housman D E; Galli S J
CS Department of Pathology, Beth Israel Hospital, Boston, Massachusetts.
NC GM45311 (NIGMS)
SO SOMATIC CELL AND MOLECULAR GENETICS, (1991 Mar) 17 (2) 207-14.
Journal code: UY2; 8403568. ISSN: 0740-7750.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199105
ED Entered STN: 19910526
Last Updated on STN: 20000303
Entered Medline: 19910506

L19 ANSWER 7 OF 12 MEDLINE
AN 91015383 MEDLINE
DN 91015383 PubMed ID: 1699134
TI **Embryonic** expression of a haematopoietic **growth factor** encoded by the Sl locus and the ligand for c-kit.
AU Matsui Y; **Zsebo K M**; Hogan B L
CS Department of Cell Biology, Vanderbilt University Medical School, Nashville, Tennessee 37232-2172.
SO NATURE, (1990 Oct 18) 347 (6294) 667-9.
Journal code: NSC; 0410462. ISSN: 0028-0836.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199011
ED Entered STN: 19910117
Last Updated on STN: 20000303
Entered Medline: 19901121

L19 ANSWER 8 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1992:499268 BIOSIS
DN BA94:117793
TI DERIVATION OF PLURIPOTENTIAL **EMBRYONIC** STEM CELLS FROM MURINE PRIMORDIAL GERM CELLS IN CULTURE.
AU MATSUI Y; **ZSEBO K**; HOGAN B L M
CS DEP. CELL BIOL., VANDERBILT UNIV. MED. SCH. NASHVILLE, TENN. 37332.
SO CELL, (1992) 70 (5), 841-847.
CODEN: CELLB5. ISSN: 0092-8674.
FS BA; OLD
LA English

L19 ANSWER 9 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1992:118839 BIOSIS
DN BA93:64639
TI ACTIVATION OF THE HUMAN C-KIT PRODUCT BY LIGAND-INDUCED DIMERIZATION MEDIATES CIRCULAR ACTIN REORGANIZATION AND CHEMOTAXIS.
AU BLUME-JENSEN P; CLAESSON-WELSH L; SIEGBAHN A; **ZSEBO K M**; WESTERMARK B; HELDIN C-H
CS LUDWIG INSTITUTE CANCER RESEARCH, BOX 595, BIOMEDICAL CENTER, S-751 24 UPPSALA, SWED.
SO EMBO (EUR MOL BIOL ORGAN) J, (1991) 10 (13), 4121-4128.
CODEN: EMJODG. ISSN: 0261-4189.
FS BA; OLD
LA English

L19 ANSWER 10 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1991:477880 BIOSIS
DN BA92:111640
TI EFFECTS OF THE STEEL GENE PRODUCT ON MOUSE PRIMORDIAL GERM CELLS IN CULTURE.
AU GODIN I; DEED R; COOKE J; **ZSEBO K**; DEXTER M; WYLIE C C
CS WELLCOME/CRC INST. DEP. ZOOL., UNIV. CAMBRIDGE, TENNIS COURT RD., CAMBRIDGE CB2 1QR, UK.
SO NATURE (LOND), (1991) 352 (6338), 807-809.
CODEN: NATUAS. ISSN: 0028-0836.
FS BA; OLD
LA English

L19 ANSWER 11 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1991:227259 BIOSIS
DN BA91:118719
TI STEM CELL FACTOR SCF A NOVEL HEMATOPOIETIC **GROWTH FACTOR** AND LIGAND FOR C-KIT TYROSINE KINASE RECEPTOR MAPS ON HUMAN CHROMOSOME 12 BETWEEN 12Q14.3 AND 12QTER.
AU GEISSLER E N; LIAO M; BROOK J D; MARTIN F H; **ZSEBO K M**; HOUSMAN D E; GALLI S J
CS DEP. PATHOL., BETH ISRAEL HOSP., BOSTON, MASS. 02115.
SO SOMATIC CELL MOL GENET, (1991) 17 (2), 207-214.
CODEN: SCMGDN. ISSN: 0740-7750.
FS BA; OLD
LA English

L19 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2001 BIOSIS
AN 1991:12325 BIOSIS
DN BR40:655
TI **EMBRYONIC** EXPRESSION OF A HEMATOPOIETIC **GROWTH FACTOR** ENCODED BY THE SL LOCUS AND THE LIGAND FOR C-KIT.
AU MATSUI Y; **ZSEBO K M**; HOGAN B L M
CS DEP. CELL BIOL., VANDERBILT UNIV. MED. SCH., NASHVILLE, TENN. 37232-2172, USA.
SO Nature (London), (1990) 347 (6294), 667-669.
CODEN: NATUAS. ISSN: 0028-0836.
FS BR; OLD
LA English

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2001 ACS
AN 1991:18592 CAPLUS
DN 114:18592
TI **Embryonic** expression of a hematopoietic **growth factor** encoded by the Sl locus and and the ligand for c-kit
AU Matsui, Yasuhisa; **Zsebo, Kristina M.**; Hogan, Brigid L. M.
CS Med. Sch., Vanderbilt Univ., Nashville, TN, 37232-2172, USA
SO Nature (London) (1990), 347(6294), 667-9
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English

L16 ANSWER 2 OF 2 MEDLINE
AN 91015383 MEDLINE
DN 91015383 PubMed ID: 1699134
TI **Embryonic** expression of a haematopoietic **growth factor** encoded by the Sl locus and the ligand for c-kit.
AU Matsui Y; **Zsebo K M**; Hogan B L
CS Department of Cell Biology, Vanderbilt University Medical School, Nashville, Tennessee 37232-2172.
SO NATURE, (1990 Oct 18) 347 (6294) 667-9.
Journal code: NSC; 0410462. ISSN: 0028-0836.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199011
ED Entered STN: 19910117
Last Updated on STN: 20000303
Entered Medline: 19901121

(FILE 'HOME' ENTERED AT 11:13:12 ON 31 MAY 2001)

FILE 'REGISTRY' ENTERED AT 11:13:23 ON 31 MAY 2001
E ZSEBO KRISZTINA

FILE 'CAPLUS, MEDLINE, BIOSIS, USPATFULL' ENTERED AT 11:16:50 ON 31 MAY 2001
E ZSEBO/AU

L1	56	S	E4
L2	180	S	E5
L3	14	S	(L1 OR L2) AND EMBRYONIC
L4	1	S	E12
L5	1	S	E11
L6	3	S	E10
L7	1	S	E9
L8	1	S	E8
L9	1	S	E7
L10	1	S	E6
L11	23	S	(L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10)
L12	15	S	(L11 OR L2 OR L3) AND EMBRYONIC
L13	12	S	L12 AND ((GROWTH FACTOR) OR GH)
L14	39	S	(METANEPHRIC TISSUE)
L15	0	S	L13 AND L14
L16	2	S	L13 AND TISSUE

(FILE 'HOME' ENTERED AT 09:24:23 ON 31 MAY 2001)

FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL' ENTERED AT 09:24:58 ON 31 MAY 2001

FILE 'REGISTRY' ENTERED AT 09:26:03 ON 31 MAY 2001
E METANEPHRIC/CN

FILE 'CAPLUS' ENTERED AT 09:26:03 ON 31 MAY 2001
E METANEPHRIC/
L1 313 S E3
E EMBRYONIC
L2 49599 S E3
L3 140 S L1 AND L2
L4 35 S L3 AND (GROWTH FACTOR)
L5 0 S L4 AND PRETREAT?
L6 6 S L4 AND TREAT?
E PRETREAT/
L7 464 S E3
L8 0 S L3 AND L7
L9 52452 S E11

=> d l6 1-6

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 2000:132096 CAPLUS
DN 132:232366
TI BMP-4 affects the differentiation of **metanephric** mesenchyme and reveals an early anterior-posterior axis of the **embryonic** kidney
AU Raatikainen-Ahokas, Anne; Hytonen, Marjo; Tenhunen, Auri; Sainio, Kirsi; Sariola, Hannu
CS Developmental Biology Research Program, University of Helsinki, Helsinki, Finland
SO Dev. Dyn. (2000), 217(2), 146-158
CODEN: DEDYEI; ISSN: 1058-8388
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 62
RE
(1) Amthor, H; Development 1999, V126, P1041 CAPLUS
(2) Attar, R; Am J Pathol 1998, V152, P1225 CAPLUS
(3) Barasch, J; Am J Physiol 1996, V271, PF50 CAPLUS
(4) Barasch, J; Am J Physiol 1997, V273, PF757 CAPLUS
(5) Bellusci, S; Development 1996, V122, P1693 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1999:668604 CAPLUS
DN 132:59531
TI Vascular endothelial **growth factor** induces nephrogenesis and vasculogenesis
AU Tufro, Alda; Norwood, Victoria F.; Carey, Robert M.; Gomez, R. Ariel
CS Departments of Pediatrics, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA
SO J. Am. Soc. Nephrol. (1999), 10(10), 2125-2134
CODEN: JASNEU; ISSN: 1046-6673
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 46
RE
(2) Alon, T; Nat Med 1995, V1, P1024 CAPLUS
(4) Brown, L; Lab Invest 1997, V76, P245 CAPLUS
(6) Carmeliet, P; Nature 1996, V380, P435 CAPLUS
(9) Conn, G; Proc Natl Acad Sci USA 1990, V87, P2628 CAPLUS
(10) Dumont, D; Dev Dyn 1995, V203, P80 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1998:759725 CAPLUS
DN 130:108029
TI Isolation of rat fibrillin-1 cDNA and its relevance in **metanephric** development
AU Kanwar, Yashpal S.; Ota, Kosuke; Yang, Qiwei; Kumar, Anil; Wada, Jun; Kashihara, Naoki; Peterson, Darryl R.
CS Department of Pathology, Northwestern University Medical School, Chicago, IL, 60611, USA
SO Am. J. Physiol. (1998), 275(5, Pt. 2), F710-F723
CODEN: AJPHAP; ISSN: 0002-9513

PB American Physiological Society
DT Journal
LA English
RE.CNT 43
RE
(1) Cazenave, C; Nucleic Acids Res 1989, V17, P4255 CAPLUS
(2) Chirgwin, J; Biochemistry 1979, V18, P5294 CAPLUS
(3) Chomczynski, P; Anal Biochem 1987, V162, P156 CAPLUS
(4) Cleary, E; Int Rev Connect Tiss Res 1983, V10, P97 CAPLUS
(5) Corson, G; Genomics 1993, V17, P476 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1998:638237 CAPLUS
DN 129:340183
TI Regulation of BMP7 expression during kidney development
AU Godin, Robert E.; Takaesu, Norma T.; Robertson, Elizabeth J.; Dudley, Andrew T.
CS Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, 02138, USA
SO Development (Cambridge, U. K.) (1998), 125(17), 3473-3482
CODEN: DEVPED; ISSN: 0950-1991
PB Company of Biologists Ltd.
DT Journal
LA English

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1997:520285 CAPLUS
DN 127:132187
TI Effects of TCDD on Ah receptor, ARNT, EGF, and TGF-.alpha. expression in **embryonic** mouse urinary tract
AU Bryant, Paul Lamont; Clark, George C.; Probst, Markus R.; Abbott, Barbara D.
CS Department of Biology, North Carolina Central University, Durham, NC, 27707, USA
SO Teratology (1997), 55(5), 326-337
CODEN: TJADAB; ISSN: 0040-3709
PB Wiley-Liss
DT Journal
LA English

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 1996:549124 CAPLUS
DN 125:217825
TI Comparative role of phosphotyrosine kinase domains of c-ros and c-ret protooncogenes in **metanephric** development with respect to growth factors and matrix morphogens
AU Liu, Zheng Z.; Wada, Jun; Kumar, Anil; Carone, Frank A.; Takahashi, Masahide; Kanwar, Yashpal S.
CS Department Pathology, Northwestern University Medical School, Chicago, IL,
60611, USA
SO Dev. Biol. (1996), 178(1), 133-148
CODEN: DEBIAO; ISSN: 0012-1606
DT Journal
LA English

```
=> d his

     (FILE 'HOME' ENTERED AT 09:54:34 ON 31 MAY 2001)

     FILE 'CAPLUS, BIOSIS, MEDLINE, USPATFULL, REGISTRY' ENTERED AT 09:55:17
     ON 31 MAY 2001
L1           284 S METANEPHRIC AND ((GROWTH FACTOR) OR GF)
L2           135 S L1 AND EMBRYONIC
L3             5 S L2 AND (PRE TREAT?)
```

=> d l3 1-5

L3 ANSWER 1 OF 5 USPATFULL
AN 2001:55724 USPATFULL
TI DNS encoding stem cell factor
IN Zsebo, Krisztina M., Thousand Oaks, CA, United States
    Bosselman, Robert A., Thousand Oaks, CA, United States
    Suggs, Sidney V., Newbury Park, CA, United States
    Martin, Francis H., Thousand Oaks, CA, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6218148 20010417
AI US 1993-172329 19931221 (8)
RLI Continuation of Ser. No. US 1992-982255, filed on 25 Nov 1992, now
    abandoned Continuation-in-part of Ser. No. US 1990-589701, filed on 1
    Oct 1990, now abandoned Continuation-in-part of Ser. No. US
1990-573616,
    filed on 24 Aug 1990, now abandoned Continuation-in-part of Ser. No. US
    1990-537198, filed on 11 Jun 1990, now abandoned Continuation-in-part
of
    Ser. No. US 1989-422383, filed on 16 Oct 1989, now abandoned
DT Utility
LN.CNT 5318
INCL INCLM: 435/069.500
    INCLS: 435/172.300; 435/252.300; 435/320.100; 435/006.000; 536/023.500;
           536/024.300
NCL NCLM: 435/069.500
    NCLS: 435/006.000; 435/252.300; 435/320.100; 536/023.500; 536/024.300
IC [7]
    ICM: C12N015-19
    ICS: C12N015-00
EXF 424/85.1; 435/6; 435/69.5; 435/172.3; 435/240.2; 435/252.3; 435/320.1;
    530/351; 536/23.5; 536/24.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 5 USPATFULL
AN 2001:44359 USPATFULL
TI Stem cell factor and compositions
IN Zsebo, Krisztina M., Thousand Oaks, CA, United States
    Bosselman, Robert A., Thousand Oaks, CA, United States
    Suggs, Sidney V., Newbury Park, CA, United States
    Martin, Francis H., Thousand Oaks, CA, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6207802 20010327
AI US 1994-336728 19941109 (8)
RLI Continuation of Ser. No. US 1992-982255, filed on 25 Nov 1992
    Continuation-in-part of Ser. No. US 1990-589701, filed on 1 Oct 1990,
    now abandoned Continuation-in-part of Ser. No. US 1990-573616, filed on
    24 Aug 1990, now abandoned Continuation-in-part of Ser. No. US
    1990-537198, filed on 11 Jun 1990, now abandoned Continuation-in-part
of
    Ser. No. US 1989-422383, filed on 16 Oct 1989, now abandoned
DT Utility
LN.CNT 5321
INCL INCLM: 530/351.000
    INCLS: 530/395.000; 530/402.000; 530/403.000; 530/404.000; 530/405.000;
           530/810.000; 424/085.100; 424/085.200; 424/085.400
NCL NCLM: 530/351.000
    NCLS: 424/085.100; 424/085.200; 424/085.400; 530/395.000; 530/402.000;

530/403.000; 530/404.000; 530/405.000; 530/810.000
IC [7]
ICM: C07K014-52
ICS: A61K038-19
EXF 424/85.1; 424/85.4; 530/350; 530/351; 530/829; 530/395; 530/402-405; 530/810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 5 USPATFULL
AN 2001:44012 USPATFULL
TI Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
IN Zsebo, Krisztina M., Thousand Oaks, CA, United States
Bosselman, Robert A., Thousand Oaks, CA, United States
Suggs, Sidney V., Newbury Park, CA, United States
Martin, Francis H., Thousand Oaks, CA, United States
PA Amgen Inc., Thousands Oaks, CA, United States (U.S. corporation)
PI US 6207454 20010327
AI US 1998-224681 19981231 (9)
RLI Division of Ser. No. US 1998-5893, filed on 12 Jan 1998 Division of Ser.
No. US 1995-449653, filed on 24 May 1995 Division of Ser. No. US 1993-172329, filed on 21 Dec 1993 Continuation of Ser. No. US 1992-982255, filed on 25 Nov 1992 Continuation-in-part of Ser. No. US 1990-589701, filed on 1 Oct 1990, now abandoned Continuation-in-part of Ser. No. US 1990-573616, filed on 24 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-537198, filed on 11 Jun 1990, now abandoned Continuation-in-part of Ser. No. US 1989-422383, filed on 16 Oct 1989, now abandoned
DT Utility
LN.CNT 5374
INCL INCLM: 435/455.000
INCLS: 435/440.000; 435/456.000; 435/458.000
NCL NCLM: 435/455.000
NCLS: 435/440.000; 435/456.000; 435/458.000
IC [7]
ICM: C12N015-00
ICS: C12N015-85; C12N015-86; C12N015-87; C12N015-88
EXF 424/85.1; 424/450; 536/23.1; 514/44; 514/2; 435/325; 435/455; 435/440; 530/402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 5 USPATFULL
AN 2001:43975 USPATFULL
TI DNA encoding stem cell factor
IN Zsebo, Krisztina M., 1043 Mountain Oak Pl., Thousand Oaks, CA, United States 91300
Bosselman, Robert A., 3301 Baccarat, Thousand Oaks, CA, United States 91362
Suggs, Sidney V., 509 Sierra Heights Ct., Newbury Park, CA, United States 91320
Martin, Francis H., 337 N. Greenmeadow Ave., Thousand Oaks, CA, United States 91320
PI US 6207417 20010327
AI US 1995-482918 19950607 (8)
RLI Division of Ser. No. US 1993-172329, filed on 21 Dec 1993 Continuation-in-part of Ser. No. US 1990-589701, filed on 1 Oct 1990 Continuation-in-part of Ser. No. US 1990-573616, filed on 24 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-537198, filed on 11 Jun 1990, now abandoned Continuation-in-part of Ser. No. US 1989-422383, filed on 16 Oct 1989, now abandoned
DT Utility
LN.CNT 5281
INCL INCLM: 435/069.500
INCLS: 435/172.300; 435/252.300; 435/320.100; 435/006.000; 536/023.500; 536/024.300

NCL NCLM: 435/069.500
NCLS: 435/006.000; 435/252.300; 435/320.100; 536/023.500; 536/024.300
IC [7]
ICM: C12N015-19
ICS: C12N015-00
EXF 536/23.5; 435/69.1; 435/69.5; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 5 USPATFULL
AN 2001:40577 USPATFULL
TI Stem cell factor
IN Zsebo, Krisztina M., Thousand Oaks, CA, United States
Bosselman, Robert A., Thousand Oaks, CA, United States
Suggs, Sidney V., Newbury Park, CA, United States
Martin, Francis H., Thousand Oaks, CA, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6204363 20010320
AI US 1992-982255 19921125 (7)
RLI Continuation of Ser. No. US 1991-684535, filed on 10 Apr 1991, now abandoned Continuation-in-part of Ser. No. US 1990-589701, filed on 1 Oct 1990, now abandoned Continuation-in-part of Ser. No. US 1990-573616,
filed on 24 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1990-537198, filed on 11 Jun 1990, now abandoned Continuation-in-part of
Ser. No. US 1989-422383, filed on 16 Oct 1989, now abandoned
DT Utility
LN.CNT 5298
INCL INCLM: 530/351.000
INCLS: 530/395.000; 424/085.100
NCL NCLM: 530/351.000
NCLS: 424/085.100; 530/395.000
IC [7]
ICM: C07K014-52
EXF 530/350; 530/351; 530/395; 435/69.1; 930/120; 930/140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

6,207,802

=> d l3 2 kwic

L3 ANSWER 2 OF 5 USPATFULL

SUMM . . . This cell line produces a factor which stimulates both early myeloid and lymphoid cell types. It has been termed hemolymphopoietic **growth factor** 1 (HLGF-1). It has an apparent molecular weight of 120,000 [McNiece et al., Exp. Hematol., 16, 383 (1988)].

DETD There is **embryonic** expression of SCF by cells in the migratory pathway and homing sites of melanoblasts, germ cells, hematopoietic cells, brain and. . .

DETD . . . cells, neural crest derived melanocytes, commissural axons originating from the dorsal spinal cord, crypt cells of the gut, mesonephric and **metanephric** kidney tubules, and olfactory bulbs is of benefit in states where specific tissue damage has occurred to these sites. SCF is useful for treating neurological damage and is a **growth factor** for nerve cells. SCF is useful during in vitro fertilization procedures or in treatment of infertility states. SCF is useful. . .

DETD . . . that neoplastic cells cycle more actively than normal cells, SCF alone or in combination with other factors acts as a **growth factor** for neoplastic cells and sensitizes them to the toxic effects of chemotherapeutic drugs. The overexpression of SCF receptors on leukemic. . .

DETD . . . (dog, ATCC CCL 183), bovine endothelial cell line (provided by Yves DeClerck, Childrens Hospital Los Angeles, Los Angeles, Calif.), feline **embryonic** fibroblast cell line (Jarrett et al., J. Gen. Virology, 20:169-175 (1973)) and chicken brain RNA. The primer used in first. . .

DETD . . . 3.times.10.sup.5 donor cells which had been treated with SCF (600 U/ml) at 37.degree. C. for 20 min and injected together (**pre-treated** group in FIG. 23). (One unit of SCF is defined as the amount which results in half-maximal stimulation in the. . . SCF-treated groups the donor marrow is engrafted faster than in the untreated control group. By 29 days post-transplantation, the SCF **pre-treated** group had converted to donor phenotype. This Example illustrates the usefulness of SCF therapy in bone marrow transplantation.

DETD . . . IL-7 (rhIL-7) was obtained from Biosource International (Westlake Village, Calif.). When rrSCF.sup.1-164 was added in combination with the pre-B cell **growth factor** IL-7, a synergistic increase in colony formation was observed (Table 16), indicating a stimulatory role of rrSCF 164 on early. . .

DETD . . . to 500 or 1000/mm.sup.3, is accelerated when either SCF or G-CSF is administered compared to control animals that received no **growth factor** (Table 21). Recovery was 2-6 days earlier in animals that received SCF than it was in those that received no **growth factor**. As noted above, combinations of appropriate growth factors with SCF will accelerate and enhance the response to those growth factors. . .

Stem cell factors

6,204,363

=> d 13 5 kwic

L3 ANSWER 5 OF 5 USPATFULL

SUMM . . . This cell line produces a factor which stimulates both early myeloid and lymphoid cell types. It has been termed hemolymphopoietic **growth factor** 1 (HLGF-1). It has an apparent molecular weight of 120,000 [McNiece et al., Exp. Hematol., 16, 383 (1988)].

DETD There is **embryonic** expression of SCF by cells in the migratory pathway and homing sites of melanoblasts, germ cells, hematopoietic cells, brain and. . .

DETD . . . cells, neural crest derived melanocytes, commissural axons originating from the dorsal spinal cord, crypt cells of the gut, mesonephric and **metanephric** kidney tubules, and olfactory bulbs is of benefit in states where specific tissue damage has occurred to these sites. SCF is useful for treating neurological damage and is a **growth factor** for nerve cells. SCF is useful during in vitro fertilization procedures or in treatment of infertility states. SCF is useful. . .

DETD . . . that neoplastic cells cycle more actively than normal cells, SCF alone or in combination with other factors acts as a **growth factor** for neoplastic cells and sensitizes them to the toxic effects of chemotherapeutic drugs. The overexpression of SCF receptors on leukemic. . .

DETD . . . (dog, ATCC CCL 183), bovine endothelial cell line (provided by Yves DeClerck, Childrens Hospital Los Angeles, Los Angeles, Calif.), feline **embryonic** fibroblast cell line (Jarrett et al., J. Gen. Virology, 20:169-175 (1973)) and chicken brain RNA. The primer used in first. . .

DETD . . . 3.times.10.sup.5 donor cells which had been treated with SCF (600 U/ml) at 37.degree. C. for 20 min and injected together (**pre-treated** group in FIG. 23). (One unit of SCF is defined as the amount which results in half-maximal stimulation in the. . . SCF-treated groups the donor marrow is engrafted faster than in the untreated control group. By 29 days post-transplantation, the SCF **pre-treated** group had converted to donor phenotype. This Example illustrates the usefulness of SCF therapy in bone marrow transplantation.

DETD . . . IL-7 (rhIL-7) was obtained from Biosource International (Westlake Village, Calif.). When rrSCF.sup.1-164 was added in combination with the pre-B cell **growth factor** IL-7, a synergistic increase in colony formation was observed (Table 16), indicating a stimulatory role of rrSCF.sup.1-164 on early B. . .

DETD . . . to 500 or 1000/mm.sup.3, is accelerated when either SCF or G-CSF is administered compared to control animals that received no **growth factor** (Table 21). Recovery was 2-6 days earlier in animals that received SCF than it was in those that received no **growth factor**. As noted above, combinations of appropriate growth factors with SCF will accelerate and enhance the response to those growth factors. . .